Standardization of research methods employed in assessing the interaction metallic-based nanoparticles and the blood-brain barrier: present and future perspectives by Ross, Aisling M. et al.
Accepted Manuscript
Standardization of research methods employed in assessing the
interaction metallic-based nanoparticles and the blood-brain
barrier: Present and future perspectives
Aisling M. Ross, David Mc Nulty, Colm O'Dwyer, Andreas M.




To appear in: Journal of Controlled Release
Received date: 16 October 2018
Revised date: 16 January 2019
Accepted date: 17 January 2019
Please cite this article as: Aisling M. Ross, David Mc Nulty, Colm O'Dwyer, Andreas
M. Grabrucker, Patrick Cronin, John J.E. Mulvihill , Standardization of research methods
employed in assessing the interaction metallic-based nanoparticles and the blood-brain
barrier: Present and future perspectives. Corel (2019), https://doi.org/10.1016/
j.jconrel.2019.01.022
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
















Standardization of research methods employed in 
assessing the interaction metallic-based 
nanoparticles and the blood-brain barrier: present 
and future perspectives 
Aisling M. Ross
a,b















Bernal Institute, University of Limerick, Limerick, Ireland 
b
School of Engineering, University of Limerick, Limerick, Ireland 
c
School of Chemistry, University College Cork, Cork, Ireland 
d
Micro-Nano Systems Centre, Tyndall National Institute, Lee Maltings, Cork, Ireland 
e
Department of Biological Sciences, University of Limerick, Limerick, Ireland 
f
Health Research Institute, (HRI), University of Limerick, Limerick, Ireland 
g
School of Natural Sciences, University of Limerick, Limerick, Ireland 
*



















Treating diseases of the central nervous system (CNS) is complicated by the presence of the blood-brain 
barrier (BBB), a semipermeable boundary layer protecting the CNS from toxins and homeostatic disruptions. 
However, this layer also excludes almost 100% of therapeutics, impeding the treatment of CNS diseases. The 
advent of nanoparticles, in particular metallic-based nanoparticles, presents the potential to overcome this 
barrier and transport drugs into the CNS. Recent interest in metallic-based nanoparticles has generated an 
immense array of information pertaining to nanoparticles of different materials, varying sizes, morphologies, 
and surface properties. Nanoparticles with different physico-chemical properties lead to distinct 
nanoparticle-host interactions; yet, comprehensive characterization is often not completed. Similarly, in vivo 
testing has involved a mixed evaluation of parameters, including: BBB permeability, integrity, 
biodistribution, and toxicity. The methods applied to assess these parameters are inconsistent; this 
complicates the comparison of different nanoparticle-host system responses. A systematic review was 
conducted to investigate the methods by which metallic-based nanoparticles are characterized and assessed 
in vivo. The introduction of a standardized approach to nanoparticle characterization and in vivo testing is 
crucial if research is to transition to a clinical setting. The approach suggested, herein, is based on equipment 
and techniques that are accessible and informative to facilitate the routine incorporation of this standardized, 
informative approach into different research settings. Thorough characterization could lead to improved 
interpretation of in vivo responses which could clarify nanoparticle properties that result in favorable in vivo 
outcomes whilst exposing nanoparticle-specific weaknesses. Only then will researchers successfully identify 
nanoparticles capable of delivering life-saving therapeutics across the blood-brain barrier. 
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As life expectancies continue to rise throughout the world, there is a steady increase in the number of 
diagnosed cases of brain disorders such as brain tumors, Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease [1-4]. While drugs exist that appear to show potential to treat these neurological 
disorders during experimental testing, few demonstrate clinical therapeutic success [1, 5, 6]. Only ~8.2% of 
self-originated drugs for the central nervous system (CNS) successfully transition from phase I clinical trials 
to clinical approval [7]. The vast majority of these drugs are unsuccessful in progressing through phase II 
and III clinical trials, where failure is usually the result of drug inefficacy [7]. The ability to deliver drugs to 
their site of action in the CNS, at clinically significant doses, remains the greatest barrier to effective 
treatment [1, 5, 6, 8]. 
The limited penetration of drugs into the CNS is primarily attributed to the highly impermeable nature of the 
brain’s microvascular system [5]. The vessel walls, known as the blood-brain barrier (BBB), consist of a 
layer of endothelial cells, connected by tight junctions [8, 9] which display increased restrictive properties 
compared to blood vessels throughout the rest of the body [10, 11]. The primary function of the BBB is to 
restrict paracellular transport into the CNS [11, 12] with diffusion limited to small, lipophilic molecules [8, 
13] and metabolite transport typically confined to transcellular movement through the endothelial cells [8]. 
In this way, the BBB prevents the passage of many harmful substances, such as toxins and pathogens, into 
the CNS [9, 14, 15]. We refer the reader to Cardoso et al. (2010) for further information regarding the 
composition and maintenance of the BBB [16]. However, this barrier poses a significant problem for the 
treatment of CNS diseases [17] as it also prevents the transport of therapeutics from the systemic circulation 
to the brain [8, 18]. Almost 100% of large molecule drugs and ~98% of small molecule drugs cannot reach 
therapeutic levels within the brain [1, 17, 19]. Additionally, endothelial cells possess transport proteins that 
actively remove many cytotoxic drugs and antibiotics from the brain [12], severely limiting treatment 
strategies. Again, we refer the reader to Patel et al. (2009) and Chen et al. (2012) for in-depth reviews of 
BBB transport routes and strategies that can be employed by new drug delivery technologies to enhance 
delivery across the BBB [20, 21]. 
Studies now primarily focus on approaches that can be employed to transport therapeutics into the brain. One 
method involves intentional, temporary breakdown of the BBB via ultrasound [14, 20, 22, 23], inflammatory 
mediators [11], vasoactive substances [20, 22], alkylglycerols [20], or osmotic disruption [11, 20, 23]. 
Unfortunately, these methods can lead to later complications [23] such as the penetration of toxins or 
pathogens into the CNS, edema formation, or disruption to homeostasis [11]. The natural loss of BBB 
integrity is also exploited in certain brain tumors, known as the “enhanced permeability and retention effect” 
[23-26]. Malignant astrocytic gliomas such as glioblastoma, the most common and deadly brain tumor [27], 
experience loss of BBB integrity at the tumor-BBB interfaces [28, 29] resulting in “leaky” vasculature. This 
increased permeability could be utilized in treatment strategies, where drugs normally excluded from the 
brain may now penetrate the compromised BBB [30]. However, this is not an ideal strategy; leaky 
vasculature is seen primarily in later stages of glioma development [23, 31] or at the tumor core [32] while 
the BBB remains largely intact at the tumor periphery or adjacent to invading cells [32, 33]. Recently, it has 
been shown that the use of nanoparticles (NPs) could provide an effective but less invasive approach [34, 
35]. Metallic-based NPs, in particular, show promise for drug delivery. Over the last decade there have been 
a great deal of papers detailing sophisticated shape and size controlled synthesis of metallic-based 
nanoparticles [36-39]. Inherent valancies enable loading with drugs to treat neurological disorders and 
functionalization with ligands to enhance delivery across the BBB [8, 14]. Although these nanocarriers 
appear promising, further work is still needed to improve drug delivery efficiency and to address the non-
degradative properties [40] which can lead to toxicity and subsequent failure in clinical trials. The future of 
nanocarrier-based therapy depends on our ability to quantitatively compare the interaction of these diverse 
and complex NPs with the BBB.  
Currently, NPs in use are frequently poorly or inconsistently characterized [41] and there are no universally 
accepted guidelines for the in vivo testing of NPs [42]. Thus, difficulties arise in comparing the performance 
of the vast array of synthesized NP and assessing the suitability for clinical applications in CNS drug 
delivery [43] due to the diverse range of approaches currently utilized to characterize NP properties and 
analyze in vivo effects. This results in the generation of apparently contrasting results from different research 
groups, that makes interpreting NP related data difficult [42]. This review attempts to compare and contrast 
















is the potential to introduce a universal and standardized approach to test prospective NP for future clinical 
applications, using widely accessible instruments and techniques. The use of a standardized approach to 
characterize and test NPs in vivo will facilitate the creation of profiles for novel NPs. Such profiles could be 
accessed by researchers and the pharmaceutical industry to select NPs, of precise properties, that are best 
suited to specific CNS applications, based on the reported in vivo effects. Such standardization could lead to 
the discovery of NPs with the potential to carry live-saving therapeutics into the CNS.  
2 Review Methodology 
The papers reviewed herein were selected according to the PRISMA systematic review process [44]. Papers 
were found using three databases: Scopus, Academic Search Complete and Web of Science. The search was 
last conducted in July 2018 using the search strings detailed below. 
 Scopus search string:  
o (( TITLE-ABS-KEY ( "blood-brain barrier"  OR  "blood brain barrier"  OR  b-bb  OR  bbb )  
AND  TITLE-ABS-KEY ( permeability  OR  transmigration  OR  transcytosis   OR  "drug 
delivery"    )  AND  TITLE-ABS-KEY ( nano* ) )   AND  ( DOCTYPE ( ar ) )  AND  ( 
PUBYEAR  <  2018 ) AND  ( LIMIT-TO ( LANGUAGE ,  "English" ) ) 
 Academic Search Complete search string: 
o ( "blood brain barrier" OR "blood brain barrier" OR b-bb OR bbb ) AND ( permeability OR 
transmigration OR transcytosis OR "drug delivery" ) AND nano*  
o Search was completed using the default search fields which searched Article Title, the 
Abstract, the Subject Headings and Keywords. Search was limited to articles, in English, 
published before December 2017. 
 Web of Science search string: 
o TOPIC: ("blood-brain barrier" OR "blood brain barrier" OR bbb OR b-bb) AND TOPIC: 
(permeability OR transmigration OR transcytosis OR "drug delivery") AND TOPIC: 
(nano*) 
o Search was refined by DOCUMENT TYPES: ( ARTICLE ) AND LANGUAGES: ( 
ENGLISH ) TIMESPAN: 1945-2017. 
Studies were then screened and excluded if the inclusion criteria of the paper were not satisfied. Only 
original experimental research was included. Papers were excluded if the paper did not specifically 
investigate NPs that cross the BBB (e.g. papers concerned with intravascular delivery or intranasal delivery 
were excluded). Further, papers were excluded if the research did not concern metallic-based nanomaterials 
or if in vivo testing was not conducted. Finally, papers were not included if the method of delivery across the 
BBB involved intentional disruption to the BBB. Figure 1 contains a summary of the papers identified and 
excluded during the systematic review.  
3 Nanoparticles as carriers for drug delivery 
NPs are materials smaller than 100 nm in at least one dimension [45, 46]. At the macroscale most materials 
are inert, however when the same materials are assessed at the nanoscale there is an addition of extraordinary 
physico-chemical properties [46, 47]. NPs can be processed in a variety of element types [48], shapes, and 
sizes for application in a range of products and processes that benefit from the novel physical, thermal, 
optical, and biological properties [49]. Due to their potential for high stability, high drug loading capabilities, 
and controllable drug release rates many NPs are currently being considered in an effort to overcome the 
BBB and deliver drugs into the CNS through drug attachment or encapsulation [6, 17]. 
Despite the ability to cross the BBB, drug delivery facilitated by NPs can face additional challenges. 
Uncoated polymeric NPs are often identified and degraded by macrophages in circulation, leading to a 
reduced circulation time and, hence, decreased delivery to the brain [17, 45]. Similarly, lipophilic NPs 
display excellent biocompatibility and biodegradation but the hydrophobicity results in high clearance from 
the body by the reticuloendothelial system [50]. Traditionally, polymeric and liposomal NPs were 
investigated for drug delivery [51]. However, in the last 5 years, there has been a shift in interest towards 

















Metallic-based NPs, in contrast to polymeric and liposomal NPs, reportedly tend to be non-degradable and 
minimal clearance via the reticuloendothelial system is reported [40, 45]. This maximizes time in circulation, 
delaying blood elimination, and hence improving the chances of BBB penetration [52]. Additionally, a 
primary advantage of metallic-based nanoparticles is the highly sophisticated and controllable synthesis 
methods being developed [36-39]. These results in materials that can be synthesized to relatively small sizes 
(sub 10 nm) compared to polymeric NPs which reportedly tend to be in the >100 nm range [53, 54]. As it is 
well established that only very small molecules are capable of crossing the BBB, the ability to produce NPs 
in the size range of metallic-based NPs could enhance delivery across the BBB. Further, the multivalancies 
of metallic-based NPs allow functionalization with multiple ligands for specific tissue or cell targeting, 
facilitating transport across the BBB [8], in addition to loading with drugs [14]. Moreover, metallic-based 
materials, such as copper, iron and zinc, are considered to be ‘essential metals’, required for physiological 
biochemical processes and thus are typically considered non-toxic [55]. However, it is important to note that 
imbalances to homeostatic levels can lead to toxic effects [55] and so safety of ‘essential’ metals for 
application as NPs should not be assumed and must be carefully evaluated for specific clinical applications. 
As well as the potential to improve biocompatibility, NPs which have magnetic properties, such as iron 
based materials, can be used in diagnostics as contrast agents for magnetic resonance imaging (MRI) [52, 
56]. While, NPs made from high atomic number metals, such as gold, can be used in x-ray based 
radiotherapy and imaging techniques due to their tendency to absorb x-rays [57]. Such NPs are being 
investigated for ‘theranostic’ applications, whereby NPs can act as drug carriers and imaging contrast agents 
to diagnose and monitor disease progression [56, 58-60]. This takes advantage of the natural properties of the 
material, without the need for further functionalisation to achieve theranostic properties, as would be the case 
with other nanomaterials. Future efforts in NP design should aim to combine delivery and diagnostic 
properties. There have been attempts to combine a number of materials in a single NP delivery system [14, 
61-69] to harness the properties of both materials and improve NP efficacy. Work in mixed systems is likely 
to continue in coming years with the advancement of NP synthesis and improvement to CNS delivery.  
However, to further advance this field and properly understand how NP design impacts CNS delivery and 
biocompatibility, it is important that NPs are fully and consistently characterized. Differences in the reported 
in vivo effects of apparently similar NPs can be found in literature. Different research groups characterize 
and report different NP properties and the methods applied for characterization also vary. This can lead to 
NPs, with seemingly similar properties, eliciting different in vivo responses including permeation across the 
BBB, toxicity and cell damage, or biodistribution. Without thorough and consistent characterization of NPs, 
elucidation of the relationship between NP characteristics and host-system responses is likely to continue to 
evade researchers.  
3.1 Dispersion medium 
Prior to beginning characterization, the NP dispersion medium should be considered. NP physico-chemical 
and morphological properties are dependent on the media in which they are dispersed [70, 71]. For example, 
the apparent dimensions of NPs change following administration in vivo [9]. Here, liquid properties differ 
from those of dispersion medium in which they were characterized [9]. After administration, plasma proteins 
may associate with the NPs, forming a new surface named the ‘protein corona’ [72, 73]. Both synthetic and 
acquired proteins/peptides on the surface of the NP effect the biodistribution, targeting efficacy, aggregation 
and toxicity of NPs. Analysis of NPs with regards to the proteins they associate with in vivo may be 
necessary for the prediction of NP-host system interactions [73]. Both protein/protein and 
protein/nanomaterial interactions will determine some of the behavior of NPs in vivo [73, 74]. To account for 
this complexity, characterization in physiologically relevant solutions [70] should be utilized to understand 
the surface composition of NPs ex vivo. In this way, anticipated in vivo NP characteristics can be linked to 
specific in vivo responses. NPs may then be designed, aiming to either suppress protein adsorption to reduce 
off-target cell uptake, or promote controlled interaction with specific proteins to increase targeting 
efficiency. 
However, some researchers report that dispersing NPs in solutions that mimic physiological salt 
concentrations and pH results in the formation of coarse agglomerates [70] and that the application of these 
agglomerated solutions for studies can lead to results that are not representative of physiological responses 
[70, 75]. Hence, some research advocates characterization in deionized or distilled water to ensure consistent 
















What is clear is that differences in medium used for dispersion during characterization can impact the 
properties quoted in the paper. For example, the zeta potential of hydrophilic, functionalized iron oxide NPs 
characterized between pH 3.0-10.0 showed a change in zeta potential from 40 mV to approximately -30 mV 
[77]. Of the literature reviewed herein, a diverse range of dispersion media have been used (outlined in Table 
S1 in the supplementary file). Additionally, 41.3% of papers reviewed did not specify the dispersion medium 
used, to the best of the authors’ knowledge. Thus, the potential for comparing different NP properties is 
limited. Hence, standardization of a universally applied dispersion medium could facilitate clarification of 
the similarities and/or differences in the characteristics of distinct NPs.  
3.2 Traditional methods of nanoparticle characterization 
NP properties are a determining factor for suitability as CNS drug delivery systems [4, 43]. Therefore, there 
are a number of NP properties that researchers should endeavor to routinely explore during characterization. 
For example, NP size can affect the absorption, distribution and excretion of NPs [75] and shape can effect 
distribution and cellular uptake [4]. While, surface charge can have a significant effect on degree of 
agglomeration, hydrodynamic size, cellular uptake and translocation [75].  
Transmission electron microscopy (TEM) is a commonly employed, high-resolution technique used in the 
characterization of all types of NPs, including metallic-based NPs. Samples for TEM are typically prepared 
by adding a drop of the dilute NP solution to a carbon-coated copper grid and allowing evaporation of the 
solvent. TEM generated image can be used to assess core size [1, 2, 8, 9, 12, 14, 23, 24, 32, 41, 42, 61, 62, 
64, 66, 68, 77-122], dispersal [1, 9, 14, 32, 42, 64, 66, 77-80, 82-84, 88, 89, 91-96, 98, 100, 104, 106, 107, 
115, 116, 119, 120, 122-124], morphology [9, 32, 41, 42, 61, 66, 68, 79-82, 84, 87, 88, 90, 95, 97-100, 102, 
104, 105, 108, 110-132], and agglomeration/aggregation [32, 80, 90, 94, 101, 107, 108, 113, 115, 125, 126, 
131-133].  
Similarly, DLS is another common NP characterization technique that can be applied to measure zeta 
potential. For nano-sized materials there is no direct method to analyze the surface charge. Instead, zeta 
potential is calculated [76, 134]. This is a measure of the electrical potential of the double layer formed at the 
surface of a NP based on its interaction with the solution in which it is dispersed [76]. It can be utilized as an 
indication of NP stability in solution [135]. It is most commonly measured by dynamic light scattering (DLS) 
using laser Doppler velocimetry [1, 18, 23, 26, 32, 41, 42, 64, 66, 77, 78, 80, 82-89, 91, 93-95, 97-99, 101, 
102, 104, 108-110, 114, 115, 117-119, 122, 126-129, 131, 133, 136-140]. DLS also has the capacity to assess 
the hydrodynamic size [1, 12, 14, 18, 24, 26, 32, 41, 42, 68, 71, 77, 78, 80, 82-84, 87-89, 91-93, 99, 101, 
102, 104, 107-110, 114, 115, 117-120, 122, 127, 129, 130, 133, 136-143], size distribution profile [1, 2, 92, 
99, 101, 102, 107, 108, 117, 118, 124, 126, 128, 129, 131, 132, 143], and polydispersity index [1, 24, 26, 71, 
77, 78, 87, 88, 92, 99, 101, 104, 107, 110, 115, 124, 129, 140, 142] of NPs.  
TEM and DLS are standard, well-established techniques used to analyze all types of NPs. Despite this, these 
techniques are not being thoroughly applied for the characterization of metallic-based NPs for CNS 
applications (see Table S2 in the supplementary file for a list of papers that characterized NPs using TEM 
and DLS and the properties that were examined). The properties analyzed by TEM and DLS are known to 
impact NP-host system interactions and, hence, the efficacy and biocompatibility of NPs. Although most 
papers reviewed conducted some form of characterization using these techniques, none of the papers 
reviewed analyzed all of the above parameter parameters, to the best of the author’s knowledge. A 
breakdown of the frequency with which the aforementioned properties were investigated can be seen in 
Figure 2.  
However, NP phase is particularly important in situations where more than one phase occurs, such as in the 
case of iron oxide NPs. X-ray diffraction (XRD) can be used to analyze NP crystal structure/phase [61, 62, 
66, 69, 80, 87-89, 94, 96, 98, 101, 113, 118, 120, 122, 125, 126, 144-146], as well as purity [61, 80, 96, 101, 
102, 113, 120], surface coating [81, 93], or size [94]. Selected-area electron diffraction (SAED) can also be 
used to investigate crystallinity [94]. Use of a surface area analyzer (SAA) to analyze the NP surface could 
also be considered. SAAs can obtain the N2 adsorption-desorption isotherms, providing information 
regarding the surface properties of the NPs [42, 78, 87, 98, 102, 118, 120, 126, 131, 144, 145]. 
In addition to these techniques, a number of other characterization methods can be employed to supplement 
the information gained from TEM and DLS. Methods such as ultraviolet-visible spectroscopy (UV-vis), 
















(ICP-OES), inductively-coupled plasma mass spectrometry (ICP-MS), Infrared spectroscopy (IR), Fourier 
Transform Infrared spectroscopy (FTIR), x-ray photoelectron spectroscopy (XPS), electron diffraction (ED), 
energy dispersive x-ray spectroscopy (EDX), electron energy loss spectroscopy (EELS), Raman 
spectroscopy [88], and neutron activation analysis (NAA) can also be employed. These techniques are 
primarily concerned with analyzing parameters such as NP solution concentration [1, 8, 9, 26, 41, 68, 80, 85, 
103, 107, 124, 133, 137], agglomeration [9, 101, 106], stability [96], purity [94, 101, 110, 118, 120], phase 
ratio [101, 102], composition [61, 64, 87, 88, 94, 145], and/or structure [32, 62, 66, 89, 101, 122, 131]. 
While these techniques provide useful information regarding NP solutions, they do not usually provide direct 
information pertaining to the NP material properties. Therefore, it is less critical for these approaches to be 
streamlined in future research. Similarly, numerous techniques can be applied to assess ligand binding; 
however, this review focuses on characterization of the properties of the NP core, which can directly impact 
NP-host system interfaces and BBB interactions. The methods used to monitor and evaluate NP conjugation 
generally vary depending on the properties of the ligands or drugs themselves. [96] 
3.3 Alternative and additional approaches to nanoparticle characterization 
In addition to the commonly employed techniques, there are a number of alternative and novel 
characterization techniques that have not been utilized considerably. Scanning electron microscopy (SEM) 
[42, 62, 69, 98, 127, 131, 145], scanning transmission electron microscopy (STEM) [26], or STEM in 
conjunction with high angle annular darkfield detection [9] have also been applied to assess particle size 
distribution [9, 26, 98, 127, 131, 145], NP aspect ratio [26, 127], aggregation [125], and morphology [26, 42, 
62, 69, 98, 120] as an alternative to TEM. Atomic force microscopy (AFM) can also be used as an alternative 
to TEM to analyze NP size [83, 101, 145] and morphology [101], as well as phase differences [101].  
Nanoparticle tracking analysis (NTA) has been employed to determine NP size and dispersal [136] or the 
number of NPs in solution as a measure of NP concentration [41]. This concentration is then expressed as 
NP/mL rather than the traditional g/mL, whereby 1 g of NP could contain different numbers of NPs for NPs 
of different sizes [41]. However, this method is not suitable for very small NPs (e.g. 20 nm particles) [41, 
136]. 
Another alternative to TEM, for application in estimating agglomeration in vivo, is gel electrophoresis. 
Guerrero et al. (2010) estimated the physiological aggregation of NPs in blood by suspending them in 
plasma [115]. Gel electrophoresis was then applied to analyze the electrophoretic mobility of the NPs 
following interaction with the plasma proteins [115]. 
In the case of magnetic metallic-based NPs, magnetic characterization can be performed using a 
magnetometer [69, 77, 84, 85, 92, 100]. his can also be applied to examine the aggregation of magnetic 
NPs [85]. Further, the suitability of magnetic NPs for use as MRI contrast agents can be indicated by 
evaluating relaxation rates under a magnetic field using nuclear magnetic resonance (NMR) spectroscopy 
[77, 91] or an MRI [80]. Metallic-based NPs such as iron, iron oxide, cobalt, or nickel [147] are particularly 
suited for use as MRI contrast agents. However, other NPs can be doped with these metals for tailored NP 
applications [147]. Understanding the magnetic properties of these NPs will be critical in determining their 
suitability as contrast agents for CNS theranostic applications. 
Another technique that can be used to characterize the magnetic properties and dynamics of metallic-based 
NPs is electron magnetic resonance (EMS), also known as electron spin resonance (ESR) [46]. This 
technique can be used to examine the superparamagnetic properties of NP dispersions [46]. It has been found 
that the magnetic behavior of materials is closely related to size; as size increases EMR signals become less 
intense [148], further signifying the interesting physico-chemical properties associated with nano-scale 
materials.  
There are several advanced characterization techniques for nano-scale materials, which are not yet 
commonly used or widely available, but have the potential to strengthen the ability to tailor the physical 
dimensions of metallic-based NPs for use in drug delivery in future research. Standard TEM imaging enables 
the structural characterization of NPs post-synthesis, however liquid cell transmission electron microscopy 
(LCTEM) will allow for in situ imaging of NP formation during the synthesis procedure [149]. With 
nanofabricated liquid cells, it will be possible to image through liquids using TEM with sub-nanometer 
















manipulation of NPs and in situ lithiation of electrode materials for lithium-ion batteries [151-153]. This 
technique enables researchers to monitor the NP crystallization process in real time [154]. Techniques such 
as this can have important implications for real-time feedback for the development of NP synthesis processes 
that produce NPs with characteristics suitable for CNS drug delivery. 
Further expansions of this technique include the development of liquid flow transmission electron 
microscopy, whereby the TEM has been coupled with a microfluidic cell that will allow the dynamic flow of 
NPs through a hydrated environment during imaging [155]. The use of this technique combined with 3D, 
microfluidic cell culture models of the BBB [156-159] could provide an opportunity to characterize the real 
time response of NPs to physiologically relevant environment in vitro. This could offer an alternative to the 
need to conduct TEM in physiologically relevant solutions (as discussed in section 3.1) with the further 
advantage of providing information relating to the interaction of NPs with cells, mechanisms of cellular 
uptake, and permeation. Researchers could then determine the feasibility of continuing further research to in 
vivo models for clinical use.  
Additionally, characterization techniques such as in situ XRD, when coupled with a heating stage, allow for 
real-time monitoring of the crystal structure of NPs during the synthesis process and can reveal the influence 
of heating temperature on the phase and size of the NPs being prepared [160]. The application of advanced 
structural characterization techniques, such as these, will be a crucial step in the realization of metallic-based 
NPs with dimensions and morphologies which are “made-to-order” for use in CNS drug delivery 
applications. 
Another in situ technique combines in situ X-ray absorption near edge structure (XANES) and small-angle 
X-ray scattering (SAXS). Alone, XANES is used to characterize the structure and electronic properties of 
NPs [161]. This can include oxidation state, structural symmetry, and relative atomic geometries [161]. 
Meanwhile, SAXS is a technique commonly employed for structural information of biomolecules and NPs in 
addition to monitoring dynamic conformational changes [162] and to analyze size distribution, shape and 
polydispersity index of nanomaterials [163]. It is advantageous in so far as it is capable of analyzing 
materials in physiological solutions, but it lacks high resolution [162]. However, when the individual 
techniques are combined, it is possible to generate time-resolved, in situ, data on the formation of metallic-
based NPs that was previously not accessible with conventional techniques for NP formation [164, 165]. 
Polte et al. (2010) give a fresh and in-depth insight on the mechanism of gold NP formation derived from 
coupled in situ XANES and SAXS evaluation [163].  
3.4 Recommendation 
TEM and DLS are widely used and standard instruments for the assessment of many different types of NPs, 
including, but not limited to, metallic-based NPs. Together these techniques provide critical information 
concerning NP characteristics including core size, hydrodynamic size, size distribution profile, dispersal, 
morphology, zeta potential, agglomeration and polydispersity index. Variations in any one of these 
properties could impact the interaction of the NPs with the host system and should be thoroughly 
investigated prior to in vivo experiments. NPs are not routinely fully characterized in a consistently manner 
[41]. Therefore, it is the recommendation of this review that both TEM and DLS should be applied to 
measure all of the aforementioned NP properties. It is not sufficient to analyze only a subset of these 
parameters as each parameter has a unique impact of the host system response and will vary between NPs. 
Techniques such as XRD should also be considered in situations where the NP may be synthesized in 
different phases, such as iron oxide.  
Additionally, researchers should endeavor to investigate TEM and DLS properties in both deionized water 
and a physiologically relevant solution such as serum, similar to the testing conducted by Zhang et al. (2012) 
[71]. This will allow researchers to anticipate NP properties that can be expected in vivo and enable them to 
better understand how NP properties change in a physiological environment, and hence, how these changes 
might impact the host system response. These techniques should be applied, at a minimum, to characterize 
all NPs prior to in vivo testing. Figure 3 contains a summary of the recommended, minimum NP 
characterization.  
For theranostic applications, an understanding of the magnetic properties of NPs should be considered. 
Techniques such as EMS or NMR can provide important information relating to magnetic properties to 
















Supplementary to this, in the future researchers could begin to utilize novel techniques, such as LCTEM, for 
real-time in situ investigations of the NP synthesis process. Such in-line characterization steps can improve 
the synthesis of NPs of sophisticated sizes and shapes, tailored for CNS applications. The incorporation of 
this technique with microfluidic devices that model the BBB could also prove to be an interesting 
development in future NP characterization for CNS drug delivery.  
It is crucial that future investigations of nanocarrier-based drug delivery, apply a streamlined methodology 
for NP characterization. Standardization of a universal methodology, using assessable techniques, to conduct 
NP characterization could lead to more complete and comparable NP profiles. This can aid in understanding 
the impact different NP properties have on their suitability for applications in CNS drug delivery. 
4 In vivo Blood-Brain Barrier Interactions of Nanoparticles 
Once NPs have been characterized, in vivo testing can be employed to monitor the ability of NPs to cross the 
BBB, to observe NP distribution throughout CNS and the rest of the body, to assess disruption to BBB 
integrity, and to test the toxic effects of the NPs. An in vivo model is advantageous due to its replication of 
the physiological conditions that would be experienced in a clinical situation [166]. However, inconsistencies 
in the methods employed to assess these interactions presents complications when comparing results from 
different studies to evaluate the suitability of NPs for use in the treatment of CNS disease.  
4.1 In vivo System 
In vivo testing provides invaluable insight into the response of a host system to NPs administration [166]. 
However, different host systems result in distinct NP-host system interactions [167, 168]. Therefore, when 
attempting to compare the in vivo properties of NPs it is important to consider that different animal models 
may elicit distinct responses to the administered NPs and not all results will be clinically relevant. Higher 
primates are generally considered to display responses closer to those experienced in a human subject. 
However, few situations employ higher primates [169], and rodents, including Sprague−Dawley rats [1, 8, 
18, 26, 42, 84, 87, 89, 92, 93, 95, 96, 98, 100, 102, 110, 115, 116, 123, 137, 142, 146, 167, 170-174], Wistar 
rats [9, 12, 61, 62, 64, 65, 69, 77, 83, 91, 93, 105, 106, 133, 175, 176], or mice [14, 23, 24, 41, 63, 66-68, 71, 
77, 80-82, 85, 86, 88-90, 93, 94, 97, 101, 103, 104, 107-109, 111, 112, 114, 119, 124-132, 136, 138-144, 
167, 175, 177-181], remain the most commonly used animal models for in vivo testing. 
The use of the Drosophila melanogaster (fruit-fly) is emerging as a simple and potentially informative in vivo 
model of mammalian systems due to its potential for rapid results, the high conservation of genomic 
information, and the cellular and developmental mechanisms it shares with higher organisms [2, 118] 
including, specifically, similar neurophysiology [118]. Additionally, due to its rapid life cycle, the impact of 
NPs on development and aging can be assessed [2]. The use of this model is likely to increase in years to 
come due to its advantages over conventional models. 
4.2 Important parameters  
Animal models can be used to evaluate a number of parameters relating to the interaction of NPs with the 
BBB to estimate their effectiveness as CNS drug delivery vehicles. One of the most important considerations 
when assessing the suitability of NPs as drug carriers for the treatment of neurological disorders is the ability 
of the NP to penetrate the BBB and reach the CNS. Based on the literature reviewed, up to 4% of NPs 
administered (per gram of tissue) cross the BBB [1, 8, 9, 12, 18, 23, 26, 41, 42, 68, 81, 84, 87-90, 93-95, 
102-105, 111, 115, 116, 124, 136, 137, 182], or as high as 17.7% in tumor brains [68, 124, 125, 132, 142]. 
However, methods utilized to assess this are highly varied (summarized in Table 1), impacting the 
opportunity to confidently compare the results of different studies. If NPs are not capable of significant 
traversal of the BBB, the drug payload will not be delivered to the site of action at clinically relevant levels. 
Despite the importance of determining permeation, although it is examined to some extent in ~86% papers 
(Figure 4), many papers do not quantify the levels at which NPs cross the BBB.  
Once it is verified that NPs can permeate into the brain, it is important to examine the distribution of those 
NPs within the CNS. NPs within the CNS must be effectively targeted to diseased tissues or cells to be 
beneficial; incorrect targeting of drug-NP conjugates to the site of action in the CNS could reduce the 
therapeutic effect or lead to damage of healthy cortical cells. If the CNS distribution profiles of different NPs 
are identified, researchers could use these profiles to select the NP best suited to the drug delivery 
















Further to CNS distribution, although functionalization of NPs with BBB or cell targeting ligands can 
improve the accumulation of NPs in the CNS, a significant portion of NPs remain in systemic circulation or 
are delivered to systemic organs. The targeting of NPs to systemic organs limits the NPs available for 
permeation into the CNS, reducing the prospect of the NPs reaching the site of action at therapeutically 
significant levels. Information regarding the extent to which different NPs are distributed to secondary 
organs could be leveraged to improve targeting of the NPs to the brain, and away from these organs. This can 
also minimize side effects that may result from mistargeting of drug-conjugated NPs intended to reach the 
CNS. 
As NPs permeate across the BBB, in some instances, this can result in breakdown of the BBB. In certain 
cases, the intention is to cause transient, reversible disruption of the BBB to enhance NP permeability [112]. 
Whether the breakdown is intentional or not, it is important to assess the integrity of the BBB following 
treatment with NPs. Disruption to BBB integrity during treatment of CNS disorders can allow toxins and 
pathogens, normally excluded, to enter the brain, lead to disruptions of brain homeostasis or result in 
secondary side-effects [11]. Disruption to the BBB should be avoided, where possible to prevent these 
complications as they can be detrimental to patient health. The brain exists in a tightly regulated and 
controlled environment where disruptions to homeostasis can cause alterations or damage to neurological 
cells and processes. Cellular or tissue damage, as a result of the presence or accumulation of NPs in the 
brain, needs to be carefully assessed before consideration for clinical applications.  
Finally, systemic toxicological studies are necessary to determine if other adverse effects occur as a result of 
NP treatment. These harmful effects can be exacerbated by accumulation of NPs in tissues not intended to 
receive treatment. An understanding of the systemic distribution of NPs, as mentioned above, can assist in 
evaluating toxicological effects.  
Despite significant importance, these parameters are not routinely examined during in vivo testing. Often, a 
paper emphasizes one aspect of NP testing and as such, complete testing is not conducted. In such a study, a 
thorough investigation into the parameter in question is conducted. However, to consider the NP a success 
for CNS delivery, favorable outcomes for all the aforementioned parameters are necessary. Figure 4 contains 
a summary of the number of papers reviewed that examined the parameters deemed to be critical for CNS 
delivery, to the best of the authors’ knowledge.  
Further, when these parameters are examined, a variety of techniques are utilized (summarized in Table 1). 
The variety of techniques used prevents researchers from directly comparing the results of different studies. 
Section 4.3 contains a discussion of techniques commonly used to assess metallic-based NPs for applications 
in CNS drug delivery. A number of techniques can be used to assess multiple parameters. As such, the 
following section has been organized according to technique. Each technique is reviewed in terms of 
parameters that can be assessed and usefulness for evaluation of NPs for CNS drug-delivery. Only 
techniques that were deemed to be commonly employed or offer unique insight were included. Other 
techniques used can be found in Table 1.  
4.3 Techniques used in vivo testing 
4.3.1 Observation  
Observation and pathology are primarily applied to evaluate toxicological effects of NPs. Prior to euthanasia, 
preliminary evaluation of the toxic effects of NPs can be achieved by assessing the subjects’ physiological 
state. This commonly includes monitoring weight [24, 66-68, 86, 93, 95, 98, 106, 114, 116, 124, 138, 142, 
175], behavior [66-69, 86, 91, 93, 96, 98, 102, 106, 108, 111, 116, 119, 133, 137, 138, 142, 146], appearance 
[86, 133], activity [93], respiration [102, 167, 183, 184], or mortality [24, 66, 102, 108, 111, 114, 116, 142]. 
Measurements can also include body temperature [146, 183], heart rate [167, 184], mean arterial blood 
pressure [146, 167, 183, 184], arterial pH [167, 183, 184], or blood gases levels [146, 183, 184]. A variety of 
cognitive tests [86, 93, 94, 119, 137, 146, 172, 181] and motor tests [88, 89, 94, 137, 146, 172] can also be 
conducted on live animals to assess possible neurological deficits resulting from NP administration. 
Researchers primarily use observation to monitor the health of the test subject and avoid unnecessary 
discomfort or pain resulting from administration of the NPs. However, this is an initial indication of toxicity 
or health and is not sufficient for full toxicological evaluations. More in-depth and quantitative assessments 
















The fruit-fly is an interesting model that can be used to examine toxicity by monitoring the survival rates and 
behavior of treated Drosophila at different stages of development (larvae, pupae, and adults) [2]. 
Biocompatibility can be further assessed by dissecting larvae, which can survive for up to 180 minutes in 
dissection buffer [2]. Dissected larvae are then exposed to a NP solution and their survival rates are 
monitored [2]. The use of this animal model in future testing could prove to be an informative model for the 
study of NPs over the model’s lifetime, a prospect that is often not feasible with other animal models.   
4.3.2 Imaging 
In addition to observation, imaging is another technique that can be applied to live animals. In the case of 
this in situ imaging, fluorescent NP can be visualized in the brain or systemic organs by methods including 
non-invasive fluorescent imaging [23, 97, 98, 107, 114, 124-126, 128, 130, 132, 138, 142, 175] or invasive 
fluorescent imaging through a cranial window [109, 127]. Often for fluorescent imaging, NPs are tagged 
with a fluorescent label including, but not limited to, fluorescein isothiocyanate (FITC), carboxyfluoresceine, 
cy5.5, rhodamine, or N-[2-(dimethylamino)ethyl]-2-[4-[2-(pyridin-4-yl)-1,3-oxazol-5-yl]phenoxy]acetamide 
(PDMO). Fluorescent probes, such as fluorescein [18, 71, 102, 143], fluorescently tagged Dextran [127], and 
horseradish peroxidase [102], can also be used for live assessment of BBB integrity in live microscopy 
through a cranial window [127]. However, when using in situ imaging techniques, it must be noted that it is 
not possible to remove the circulating blood prior to imaging. Therefore, NPs in circulation may contribute 
to apparent NP levels in organs, and as such these techniques are not useful to accurately quantify NPs levels 
in different organs. 
For magnetic or gadolinium labelled NPs, live imaging can make use of a gamma camera [113], computed 
tomography (CT) [68, 79, 82], positron emission tomography combined with CT (PET/CT) [8], MRI [14, 24, 
32, 68, 69, 77, 80, 83, 85, 91, 92, 101, 110, 125, 141, 142, 171, 174, 175, 177, 179, 180, 186], or magnetic 
resonance spectroscopy (MRS) [110]. As well as observing NPs in the brain or different organs, MRS can be 
utilized to observe metabolic changes in the neurological environment following magnetic NP administration 
by measuring the relative concentrations of metabolites [110]. Alterations in metabolite levels in the brain 
can indicate neurotoxicity. Such nanoparticles will be well suited for use in experimental stages, allowing 
both in situ and ex vivo imaging, and for clinical use as theranostic vehicles for diagnostics and disease 
management. 
Table 1: In vivo tests conducted to assess parameters pertaining to the use of NPs in the treatment of brain disorders. (FM = 
Fluorescent Microscopy, CM = Confocal Microscopy, LM = Light Microscopy, GC = gas chromatography, B = brain, L=liver, S = 
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Alternatively, following euthanasia, ex vivo histopathological examination of major organs can be applied. 
Mounted organs can be imaged directly or sectioned and imaged at a higher resolution, ex vivo. This can 
generate information about the interaction of the NPs with the brain capillaries, transport mechanisms, post-
penetration fate, distribution to systemic organs or CNS/systemic tissue damage, including loss of BBB 
integrity. Ex vivo imaging commonly includes light microscopy [12, 24, 32, 41, 66, 67, 83, 87, 90, 93-95, 
102, 104, 112, 114, 124-126, 129, 131, 132, 136, 138, 139, 141, 142, 146, 170, 172, 173, 177, 179, 180, 183, 
184, 186-189], TEM [9, 12, 15, 26, 61, 62, 64, 83, 84, 86, 88-90, 93, 95, 102, 123, 129, 136, 140, 167, 170, 
173, 175, 176, 184, 185, 190], or STEM [9, 88, 90, 102].  
These techniques do not require fluorescent tagging to detect the NP in the tissue. However, iron oxide and 
gold NPs can be stained ex vivo with Prussian blue [83, 100, 101, 123, 130, 141, 170, 174, 177, 179, 180, 
186, 187] or silver [12, 24, 41, 124, 136, 138, 139, 142], respectively, to enhance visualization by light 
microscopy. Light microscopy can be further enhanced through with staining with Mayer’s hematoxylin [15, 
138, 139, 177] or hematoxylin and eosin staining [24, 25, 41, 42, 66, 67, 87, 88, 90, 93, 95, 112, 114, 116, 
125, 126, 129, 132, 136, 141, 142, 146, 167, 172-174, 183, 188, 189], which can indicate structural and 
morphological changes to the tissue, NP induced disruption to the BBB, or localization of NPs to damaged 
tissue for treatment. 
Meanwhile, fluorescent microscopy [1, 2, 12, 15, 23, 25, 26, 97-99, 101, 105-107, 109, 114, 115, 123-125, 
130, 132, 138, 141, 175, 188] or confocal microscopy [2, 9, 14, 24, 61, 63-65, 67, 69, 78, 90, 91, 93, 119, 
129, 142-144, 173, 174, 177, 182, 188] [63] can be applied for visualization of fluorescent or fluorescently-
labelled NPs in the brain or systemic organs. The presence of fluorescent probes in the brain can also be 
determined post-sacrifice. The tissues themselves can also be stained using a variety of dyes (Table 2). High 
resolution images can be analyzed to examine co-localization of fluorescent NPs within counter-stained cells 
or subcellular locations. This can provide information relating to the uptake and inter- or intracellular fate of 
the NPs as well as cell or tissue damage.  
Table 2: Stains employed to label tissue sections for light, fluorescent or confocal microscopy.  
Stain Labelling Reference 
4',6-diamidino-2-phenylindole (DAPI) Cell nucleus [14, 42, 61, 64, 65, 69, 90, 91, 
99, 114, 129-132, 141, 175, 
188] 
Anti-4G8 Amyloid-beta plaque [101, 177, 180] 
Anti-6E10 Amyloid-beta plaque [101, 177, 180] 
Anti-Aquaporin4 Astrocytes [42] 
Anti-brunchpilot (nc82) Neural Synapses (Drosophila) [118] 
Anti-factor VIII Endothelial cells [143] 
Anti-glial fibrillary acid protein (GFAP) Astrocytes [42, 143, 146, 183] 
Anti-lipoprotein receptor-related protein 
(LRP1) 
Glioma cells [129] 
Anti-legumain Glioma cells [132] 
Anti-low density lipoprotein receptor 


















protein 1 (anti-LAMP1) 
Cell vesicles [140] 
Anti-neuronal specific nuclear protein 
(anti-NeuN) 
Neuronal cells [14, 61, 64, 65, 67, 96] 
Anti-platelet endothelial cell adhesion 
molecule (also referred to as anti-cluster 
of differentiation 31) (anti-CD31) 
Endothelial cells [99, 130, 142, 188]  
Anti-synaptophysin Neuronal Synapses [182] 
Fluoro-Jade B  Neuronal Degeneration [119, 170] 
GP120 Golgi apparatus [2] 
Hematoxylin & Eosin  Cell cytoplasm & cell nucleus [24, 25, 32, 41, 42, 67, 87, 88, 
90, 93, 95, 98, 116, 124, 125, 
131, 136, 141, 142, 146, 172-
174, 183, 188, 189] 
Hoechst 33258 Cell nucleus [63, 105, 109] 
Lectin Endothelial cells [109, 144] 
Lyxol Fast  Axon myelination [94, 146, 167, 177, 186] 
Masson’s Trichrome Cell nucleus & collagen [186] 
Nissl Stain Neuronal cells [1, 90, 115, 119, 167, 170, 
172, 173, 183, 184, 188] 
Nuclear Fast Red Cell nucleus [179, 187] 
Streptavidin-CY3 Biocytin-loaded neurons  [118] 
Toluylene Red Neural Cells [100] 
Terminal Deoxynucleotidyl Transferase 
dUTP Nick End Labelling (TUNEL)  
Apoptotic cells [114, 123, 142] 
Although imaging techniques provide useful information regarding mechanisms involved in NP permeation 
and distribution throughout the CNS, as well as offering indications of tissue toxicity, they are less valuable 
for analyzing degree of permeation. Imaging methods are primarily qualitative or semi-quantitative. As such 
alternative techniques should be applied when quantitatively assessing the permeation of NPs into the CNS 
and NP levels in systemic organs.  
4.3.3 Spectroscopy and Chromatography 
Spectroscopic methods can have useful applications in NP quantification. They can be used to quantify NP 
levels in the CNS, in different regions of the CNS (distribution), or in systemic organs. The most commonly 
employed spectroscopic method to quantify BBB permeability in the literature reviewed was ICP-MS [8, 9, 
12, 24, 41, 68, 81, 86-90, 93, 95, 102, 124, 125, 136-138, 142, 182]. It was also applied to quantify the 
distribution of NPs within different regions of the CNS [12, 68, 86, 87, 124, 137, 142], and in systemic 
organs [9, 12, 24, 41, 68, 89, 90, 102, 103, 109, 125, 137, 138, 142, 182]. The quantification of NPs in 
different regions of the CNS could indicate the NPs are able to reach the site of action in quantities capable 
of achieving a therapeutic effect. Meanwhile, NP levels in urine and blood can also be quantified. Urine or 
feces levels indicate renal clearance of the NPs [24, 41, 109, 124, 137] while blood samples can provide 
information on NP blood retention and pharmacokinetics [24, 41, 89, 95, 102, 103, 109, 124, 142, 189]. ICP-
OES [23, 42, 82, 84, 103, 104, 132] or atomic absorption spectroscopy (AAS) [79, 82, 94, 111, 116] have 
been similarly applied to measure the permeation of NPs into the brain [23, 42, 79, 82, 84, 94, 104, 111, 116, 
132], distribution to systemic organs [79, 82, 84, 103, 104, 111, 116] or blood and urine levels [79, 82, 104, 
111, 116].  
Alternatively, the quantity of NPs in brain tissue or systemic organs can be deduced using NAA which 
creates a radioactive NP [1, 26, 115]. The brain is first removed and lyophilized, before sealing by friction 
welding. It is then exposed overnight to a neutron flux to generate a radioactive sample [1]. The γ-rays 
emitted by the samples can be counted using a germanium detector coupled to a γ -ray spectrometer to 
quantify NP concentration [1, 115]. NAA and ICP-MS are considered to be the current gold standards for the 
quantification of gold in tissue samples [1, 26]. NAA is considered more sensitive than ICP-MS, which in 
turn is more sensitive than AAS [1]. Thus, methods such as NAA or ICP-MS may be preferable for 
















For fluorescent or fluorescently tagged NPs, UV-vis [106, 131] or fluorescent spectroscopy [98, 99, 175, 
179] have been applied to determine relative brain [106, 175], systemic organ [98, 106, 175] or blood [98, 
99, 131, 188] concentration of homogenized tissue samples. Fluorescent spectroscopy [42, 94, 172, 189], as 
well as HPLC [86, 133], are further used in in a number of biochemical assays to determine neurotoxicity 
Changes in the levels of these neurotransmitters in brain homogenate or blood can indicate deregulation in 
the brain, which can affect cognition [86, 172] or BBB dysfunction [172].  
4.3.4 Albumin Penetration 
Fluorescent dyes have significant use in analyzing BBB integrity. Extravasation of Evan’s Blue dye is the 
most commonly applied method to analyze BBB disruption [14, 15, 42, 67, 87, 94, 108, 115, 142, 146, 167, 
172, 183, 184]. The principle of Evan’s blue penetration is based on binding of the dye to serum albumin 
[42, 115, 167]. Serum albumin is typically excluded from the brain as it is not capable of crossing the intact 
BBB. Breakdown of the BBB results in increased permeability of the dye-albumin conjugate into the brain 
[115, 167]. Although visual confirmation of dye permeation into the brain is most commonly employed, 
calorimetry can be utilized for quantitative estimation of permeation of the dye-albumin conjugate [172, 183, 
184, 191]. Alternatively, brain sections can be incubated with formamide overnight and the supernatant, 
containing the dye-albumin conjugate, can be analyzed spectrophotometrically to quantify dye concentration 
[15, 67, 87, 108].  
Gamma counters can also be used to analyze BBB integrity following administration of NPs. Radioiodine 
(
131
I), a gamma reporter, will bind to albumin and the subsequent radioactivity of brain sections is monitored 
using a gamma counter [146, 167, 172, 183, 184, 191]. These methods provide a rapid and useful means of 
qualitatively assessing BBB disruption. The potential for semi-quantitative assessment further highlights the 
practicality of this technique. 
4.3.5 Fluid Homeostasis 
To monitor BBB integrity, researchers have also monitored increased water content and edema formation, or 
disruption to electrolyte levels [167]. Water content, and hence, brain edema formation, are determined by 
comparing the wet weight of the brain to the dry weight [42, 87, 146, 167, 183]. Sharma et al. considered a 
1% increase in water content indicative of edema formation [167, 183].  Similarly, electrolyte content in the 
brain can also be disrupted as BBB permeability increases and during brain edema formation [167]. Sharma 
et al. (2009) found that brain edema formation correlated well with permeation of Evan’s blue dye [167] and 
that in situations with increased BBB permeability and edema formation, potassium content decreased and 
sodium content increased [167, 168].  
4.3.6 Hematology 
Further to BBB damage, hematological studies can be employed to analyze blood serum chemistry as an 
indication of toxicological reactions [104]. Blood analysis typically includes quantifying complete blood cell 
and serum biochemical levels [42, 67, 93, 104, 138, 142] to indicate general animal health. Changes in the 
levels of inflammatory cytokines, such as chemokines, interleukins, interferons, and tumor necrosis factor, 
can also be investigated to reveal an immune response resulting from the administration of the NPs [95, 138, 
142, 182]. Levels of these inflammatory markers in the brain directly can also be measured as an indication 
of neurotoxicity [182].  
Further biochemical analysis of blood can also specifically detect hepatic marker enzymes and 
nephrotoxicity markers, which indicate liver injury and necrosis or kidney damage, respectively [104]. These 
markers can include aspartate aminotransferase [67, 88, 93, 98, 104, 116, 131, 138, 142], alanine transferase 
[67, 88, 93, 104, 116, 138, 142, 186], alkaline phosphatase [88, 93, 104, 106, 116, 138, 142], gamma-
glutamyltransferase [116], urea or blood urea nitrogen [67, 88, 93, 104, 106, 116, 131, 138, 142], uric acid 





ATPase activity which is an indicator of cell membrane depolarization and interference with cellular 
activities [106]; or lactate dehydrogenase (LDH) levels which are associated with a wide variety of organ 
pathologies [67, 94, 98, 131].  
Finally, biochemical assays for antioxidants are used to detect oxidative stress by monitoring levels 
superoxide dismutase [104], catalase [104, 106], nitric oxide [94, 104], glutathione (GTH) [106], or 
















[94, 104] can also be used to monitor reactive oxygen species (ROS) generation. Reactive oxygen species 
can be generated as a result of oxidative stress and result in cellular damage [104].  
4.3.7 Immunohistochemistry 
IHC is another technique used to monitor toxicological response. To assess loss of BBB integrity, antibody 
based staining for immunoglobulin G (IgG) [12, 174], albumin [167], claudin-5 [71, 143, 182], occludin [71, 
143], vonWillibrand Factor [182], or actin [71] have been applied. IgG, similar to albumin, is normally 
excluded from the brain [12]. Testing of brain tissue with anti-IgG can reveal the permeation of IgG into the 
brain due to disruption of the BBB [12]. The application of anti-claudin-5, anti-occludin and anti-actin will 
stain the endothelial cells of the BBB. Changes in the expression patterns of these proteins can indicate 
damage to brain microvessels and tight junctions caused by NP administration [71].  
Neuronal damage is a critical concern when using NPs as CNS drug delivery vehicles. Cysteine string 
protein (CSP) is a marker of synaptic vesicles and can indicate changes to the axonal transport pathway 
which can lead to disruptions in the transport of essential nutrients from neuronal cell bodies to the synapses, 
a crucial process for neuronal survival and growth [2]. Meanwhile, a reduction in axon myelination can be 
monitored using antibodies against myelin basic protein (MBP) [167, 173]. A reduction in MBP signifies a 
loss in axon myelination, indicative of neuronal cell damage [167].  
Neurodegeneration can also be measured by assessing glial fibrillary acid protein (GFAP) level. GFAP is 
upregulated in astrocytes, an important cell in neuroprotection [27, 42, 90, 143, 146, 173, 183], when they 
are activated by damage or stress, a process known as reactive astrogliosis [167]. This is a protective 
mechanism in the brain; in response to insult or injury, astrocytes will become reactive and form scar tissue 
to protect the rest of the brain from the identified threat [27]. Aquaporin4 (AQP4) is another astrocytic 
marker for cell stress that can be analyzed via IHC. AQP4 is a water channel protein believed to be a marker 
of BBB permeability and edema formation [42]. 
A number of proteins can also be labeled to evaluate cell stress in the CNS. Cleaved caspase-3 [94] or ADP 
ribose polymerase [94] can also be used to stain any cells for cell death or damage. Caspase-3 is involved 
apoptosis [94], while ADP ribose polymerase is overexpressed in response to cell stress, regulating processes 
such as DNA repair or cell death [94]. The over expression of these proteins in response to NP 
administration indicates DNA damage caused by ROS [94]. Liu et al. (2017a) and Liu et al. (2017b) 
examined oxidative stress and vascular damage using antibodies against phosphylated myosin light chain 
(MLC) [42, 87]. Phosphorylation of MLC caused by oxidative stress can lead to endothelial cell contraction 
and opening of the BBB [42].  
Increased cell stress can also be monitored by assessing levels of heat shock protein (HSP) [167]. Sharma et 
al. [167] investigated levels of HSP 72 kDa, a HSP implicated in neurodegenerative stress [192]. Its 
upregulation has been correlated with cell stress pathways resulting from neuropathology [167]. They found 
there was a correlation between increased HSP expression and BBB breakdown [167]. However, it is unclear 
whether it is the increased presence of NPs, occurring due to BBB leakage, which leads to increased cell 
stress or whether it is the breakdown of the BBB itself that causes cell stress. It is also possible that oxidative 
stress caused by the NPs could lead to free radical release to induce BBB breakdown via endothelial cell 
damage and, hence, a further increase in NP permeability [167, 168]. IHC techniques, when applied 
thoroughly, provide a beneficial means of assessing the toxicological effects of NPs on different cell types in 
the CNS.  
The list of markers discussed herein is nonexhaustive. Cell toxicity markers should be selected for in-depth 
analysis, as appropriate, following preliminary assessments. 
4.3.8 Future Perspectives 
The ability to directly visualize a large number of discrete molecular species inside living cells 
simultaneously would represent a significant leap forward for the understanding of complex systems and 
processes such as drug delivery through the BBB. To optimize the application of NPs for drug delivery, it is 
crucial to understand the nature of the internal barriers of target cells, as well as the spatial and temporal 
interactions of the drug-coated NPs within the cells. Recently, reported methods have made significant 
advancements in this regard and are leading the way for a better appreciation of multifarious biological 
processes. ATP assays can indicate nanoparticle induced damage to metabolic processes [143]. Meanwhile, 
















[193]. The spatial localizations of thousands of RNA species can be determined in single cells through the 
application of multiplexed error-robust fluorescence in situ hybridization (MERFISH).  
Nucleic acid assays are also likely to become more popular as a means of analyzing genetic damage. 
Chromosomal damage can be assessed using the bone marrow micronucleus test [103]. This is used to assess 
micronucleation of polychromatic erythrocytes (PCEs) resulting from fragmentation of chromosomes during 
division of erythropoeitic blast cells [103] which is indicative on genetic damage resulting from the 
interaction of cells with the NPs. Additionally, real-time polymerase chain reaction (PCR) can be used to 
quantify the messenger-RNA (mRNA) levels to detect alterations in normal cell expression profiles [71, 95, 
143, 182]. For example, inflammation can be detected by monitoring levels of pro-inflammatory cytokines 
such as tumor necrosis factor-α and interleukin-1β, or cell adhesion molecules such as intercellular adhesion 
molecule-1 and vascular cell adhesion molecule-1 [71], to examine proteins related to cell activity (e.g. 
synaptophysin for neuronal activity) [182], or to detect the expression of autophagy related genes such as 
autophagy/beclin 1 regulator 1 or autophagy related protein 3 [143]. Xu et al. (2015) used RNA profiling to 
monitor the expression of tight junction proteins, (occludin, claudin-1, tight junction protein 1, cadherin 1) 
[95]. Changes in the mRNA levels of these genes could indicate disruptions to normal BBB structure. 
Even with recent advancements, it remains challenging to image cellular processes with high sensitivity and 
selectivity under biological conditions. Fluorescence microscopy remains to be one of the most commonly 
used methods of imaging biological molecules. However, the depth of information attainable with this 
method is restricted by a “color barrier” which limits the number of resolvable colors from 2 to 5 (or 7 to 9 if 
using advanced instrumentation and analysis) [194-197]. This limitation was recently addressed by Wei et al. 
(2016) who reported on super-multiplex vibrational imaging [193]. timulated Raman scattering under 
electronic pre-resonance conditions was used to image target molecules inside living cells with 
unprecedented levels of vibrational selectivity and sensitivity (down to 250 nanomolar with a time constant 
of 1 millisecond). Additionally Wei et al. (2016) created a palette of triplebond-conjugated near-infrared 
dyes, each of which displays a single peak in Raman spectral range [193]. The pairing of these dyes with the 
advanced Raman spectroscopy techniques described, allows for the simultaneous labelling and imaging of up 
to 24 specific biomolecules. This expansion in the number of resolvable colors for fluorescent imaging from 
5 to 24 represents a significant increase in the number of biomolecules that can be imaged at the same time 
and represents a paradigm shift in the understanding of biological processes which can be achieved through 
fluorescence microscopy. This advancement holds great potential to increase future understanding of the 
function and stability of drug-coated NPs during complex biological processes such as cell/tissue penetration 
and drug-target interactions. 
Furthermore, in recent years there has been a great deal of research on the utilization of AFM for the 
characterization of nanoscale drug delivery systems. Intermittent contact mode AFM has facilitated the 
investigation of drug delivery systems by recording the elastic or adhesion behavior of particles [198]. 
Biosensing AFM enables the observation of structural details of molecular assemblies and cell surfaces and 
can be used to monitor cellular responses to drug-coated NPs [199]. Li et al. (2014) recently reported on 
monitoring of drug actions on cell membrane on the nanoscale using AFM [200]. They demonstrated that the 
actions of drug-coated NPs on cell membranes, such as topographic changes, elasticity variations and 
molecular interaction quantification, can be characterized via AFM analysis [200]. 
4.4 Recommendation 
Based on the techniques contained in Section 4.3, the authors recommend that, where possible, the following 
techniques be utilized the measure and assess the aforementioned parameters to empower full in vivo 
characterization.  
4.4.1 BBB Permeability 
A review of literature that examines NPs for CNS application, 86.2% of research conducted some form of 
BBB permeation study. The techniques used for permeability assessment were varied with some groups 
providing only qualitative information while others attempted to quantify NP permeation. In many situations, 
research groups did not explicitly study the permeation of NPs into the brain. Instead, they observed 
parameters such as CNS distribution or CNS toxicity. Although, these parameters do indicate that the NPs 
















In situ imaging techniques provide useful information pertaining to NP penetration times, without the need to 
sacrifice multiple animals across various time points. This approach can inform researchers of the kinetics of 
BBB permeation and its use should be more widely considered in future studies. Typically, during BBB 
permeation analysis, the animal is sacrificed at a specific time-point. However, it is not always known if this 
time point will reveal maximum NP levels in the brain and a wide range of permeation times, from ~1 
minute to 24 hours have been reported [14, 77, 107, 110, 113, 114, 126, 128, 132, 142].  
Although imaging can be semi-quantitative, through the use of image processing software, methods such as 
ICP-MS or NAA could be more informative. These techniques are highly sensitive, ICP-MS is routinely 
capable of detecting NPs at concentrations as low as parts per trillion [201]. Hence, they are capable of 
detecting even minimal penetration of NPs across the BBB.  
The standardization of a combination of techniques, such as in situ imagining and ICP-MS or NAA, to 
analyze NP penetration is important in determining the suitability of NPs for CNS applications. However, in 
addition to the standardization of techniques, the method of sample preparation should also be unified. In 
many situations, the capillaries and systemic blood are not removed. Capillary-associated NPs as well as 
blood-borne NPs can be detected during quantification which may not give an accurate reflection of the 
permeation of NPs into the brain. This will impact the direct comparison of different research. Sela et al. 
reported that the levels of NPs in the brain appeared to be 10 times higher when perfusion was not conducted 
[137]. Attempts to remove capillaries, by capillary depletion, and systemic blood, through perfusion, should 
be widely applied. 
4.4.2 CNS Distribution 
It is important to show, that a NP not only has the potential to cross the BBB into the brain, but also exhibits 
subsequent, effective distribution within the CNS. Qualitative imaging techniques could provide a valuable 
insight into the NP distribution and interactions with cells in the CNS. Meanwhile co-localization imaging 
facilitates visualization of NPs within diseased cells.  
The use of NP imagining labels to monitor CNS distribution is useful for both in vivo and ex vivo imaging. 
However, the use of such labels could provide false positive results should the labels become detached from 
the NP surface. As such, researchers should examine the potential in vivo detachment of the labels from the 
surface of the NPs. Observing the leaching of labels from NPs in physiological solutions could indicate the 
loss of labels from the NP surface [107, 128, 143]. Ex vivo labelling of NPs could also be used to observe the 
presence of NPs in tissue. Co-localization of the signal from the conjugated label and ex vivo stain would 
indicate retention of the label on the NP surface. Once retention is confirmed, these NPs provide a useful 
avenue to monitor distribution and penetration mechanisms. 
The design of theranostic NPs, possessing imaging capabilities in addition to drug delivery capabilities, will 
be beneficial for qualitative imaging assessments of CNS distribution further to the potential uses in clinical 
diagnostics and disease progression. As such, standard light or fluorescent imaging strategies can be most 
useful for qualitative assessment of NP distribution in the CNS. However, dissection of the brain into regions 
of interested, followed by quantitative assessment, can also be conducted.  
4.4.3 Systemic Distribution 
Evaluating NP content in secondary organs can further inform researchers of how NPs are taken up by other 
organs or cleared from the body. The uptake of NPs by secondary organs will reduce NPs available for 
permeation into the CNS. By reducing secondary organ uptake and increasing circulation time, the ability of 
the NPs to permeate through the BBB and reach their site of action at therapeutically significant levels could 
be improved. Techniques such as ICP-MS or NAA can provide quantitative data relating to NP distribution. 
Quantification of organ levels, relative to the administered dose, can then be compared to brain levels. This 
can then be leveraged to inform researchers on how different NP properties or ligands and modifications can 
improve blood half-life and increase BBB permeation.  
4.4.4 Blood-Brain Barrier Integrity 
Once distribution has been determined, damage induced by the NPs must be considered. This review found 
that just 25.7% of literature examined the integrity of the BBB following NP administration (Figure 4). Of 
these studies, BBB integrity is most commonly analyzed using Evan’s Blue dye. This method provides 
simple, visual confirmation of the breakdown of the BBB through the permeation of dye into the brain tissue. 
















intensity testing to obtain a semi-quantitative assessment of disruption to the BBB in different regions of the 
brain. This semi-quantitative method could be universally applied in future testing to provide a simple but 
informative measure of the integrity of the BBB following NP administration. Similar to BBB permeation, 
perfusion should be conducted prior to attempting to quantify Evan’s blue permeation.  
Although damage to the BBB is not desirable due to the potential for secondary complications, it is worth 
noting that this might offer a potential opportunity for the delivery of a greater quantity of therapeutics to the 
brain. As is the case with brain tumors, increased permeation of NPs into the brain is noted compared to 
healthy brains [68, 124, 132], potentially due to loss of BBB integrity associated with this disease. Thus, 
following repeated administration, NP levels in the brain could increase with each dose. Notwithstanding, the 
effect of repeated NP administration warrants further investigation. 
4.4.5 CNS Toxicity 
To further assess NP-induced damage, microscopic analysis of brain sections can reveal morphological or 
structural changes to the tissue. Different applications and diseases will target different cells or processes. 
Thus, the cells and regions examined will vary with each specific application. However, it is also important 
to note that NPs may result in toxic effects to cells or regions other than the intended target. For this reason, a 
preliminary microscopic assessment could be important to indicate the regions or cells that require further 
toxicity examination. 
Based on the results of the initial assessment, more cell specific tests can be conducted using techniques such 
as IHC. IHC analysis of cell specific proteins or process can provide further information on cell toxicity or 
damage. The list of proteins mentioned in this review is non-exhaustive and research groups should make an 
informed decision, based on a preliminary assessment, as to the most appropriate proteins or processes to test 
in each specific situation. 
4.4.6 Systemic Toxicity 
Finally, systemic toxicity as a result of NP administration must not be ignored. Observation offers a simple 
indication of systemic toxicity but to obtain informative results, a more in-depth analysis of the toxicological 
affects can be gleaned through thorough hematology and histopathology. Hematological assessment provides 
information of systemic response through the analysis of proteins and metabolites in the blood. Alterations to 
these levels can indicate damage to specific tissues such as the kidneys and liver or the initiation of an 
immune response. Histopathological assessment can indicate changes to tissue structure and morphology, in 
particular. These assessments can in turn guide further toxicity studies to explore specific toxicological 
responses in these tissues.  
A summary of the recommended approach for in vivo testing of metallic-based NPs for CNS applications is 
given in Figure 5. The comprehensive inclusion of these tests could help improve the outcomes of clinical 
trials through the use of a thorough inspection process for NP suitability. 
5 Conclusion 
NPs show significant promise for the treatment of CNS diseases. The controllable properties of metallic-
based NPs offer the potential to traverse the BBB, moving from circulation into the brain. Additionally, the 
multivalancies and high surface to volume ratio are ideal for functionalization with ligands to enhance CNS 
targeting or for conjugation with therapeutics. Once these nanocarriers have permeated into the brain, they 
may deliver lifesaving drugs to the CNS which would otherwise have been excluded. 
The wide range of metallic-based NPs available presents challenges in selecting suitable platforms for 
therapeutic delivery to the CNS. Characteristics such as size, morphology, surface charge and agglomeration 
play a crucial part in the NP-host system interaction and, particularly, the ability of NPs to cross the BBB. 
Changes in any one of these NP properties can result in a different host system response. Before attempting 
to evaluate the NP-host system responses, comprehensive profiling should be conducted. NPs in use are 
frequently poorly or inconsistently characterized [41]. Techniques such as TEM and DLS are valuable tools 
in NP characterization, not unique to metallic-based NPs, that provide information pertaining to core size, 
hydrodynamic size, size distribution profile, dispersal, morphology, zeta potential (as an estimation of 
surface charge), agglomeration and polydispersity index. Although these techniques are considered 
‘common-place’ in nanoparticle testing, they are not being routinely applied to generate complete NP 
















towards the unification of NP characterization. Additionally, the dispersal medium used during NP testing 
can result in differences in the values obtained for NP properties. Characterization in deionized water 
presents an evaluation of NP properties, independent of exogenous factors, which can be leverage during the 
synthesis process. However, characterization in a physiologically relevant solution, such as serum, offers the 
opportunity to assess the potential properties of NPs following in vivo administration. It is our 
recommendation that NP properties be evaluated in both deionized water and in serum using TEM and DLS, 
at a minimum, as outlined in Figure 6. This will provide critical information pertaining to the properties of 
various NPs. A thorough understanding of these properties will benefit elucidation of how different 
properties impact the NP-host system response. This information can be leveraged by future researchers to 
inform the NP synthesis for the production of NPs with properties capable of overcoming the BBB. 
Following this, similar difficulties arise during in vivo assessments. In vivo models provide vital information 
in the move towards clinical applications; offering an opportunity to monitor the effects of NPs in a living 
system. Rodents are the most commonly used animal model due to ease of use and availability although the 
use of the Drosophila melanogaster may prove to be an interesting and informative model in future studies 
for evaluation of NP effects on development and lifecycle. The various host systems that can be selected for 
NP assessment can potentially lead to different in vivo responses following NP administration. Thus, it is 
important to be aware that direct comparisons of NPs, tested in different animal models may not be possible. 
Further, the testing carried out by different groups to assess the suitability of NPs for use in CNS treatment 
applications is varied. Few research groups conduct studies to experimentally investigate and compare the in 
vivo responses of different NPs. Additionally, comparisons of NPs from literature are hindered by the diverse 
range of parameters evaluated and test methods used. Parameters such as permeability of NPs across the 
BBB, NP distribution within the CNS and throughout the body, BBB integrity following administration, and 
toxicological response are all vital in determining NP suitability. A summary of the recommended 
parameters that should be considered and suggested methods of evaluation are given in Figure 6. Briefly:  
 Prior to conducting any in vivo analysis, through characterization of the NPs in use should be 
conducted. This should include characterization in deionized water to facilitate an understanding of 
the properties of the synthesized NPs. Next the NPs should be characterized in a physiological 
solution, such as serum, to understand how the properties of the NPs will change once administered. 
This characterization should include, at a minimum, the use of TEM and DLS to investigate core 
size, dispersal, morphology, agglomeration/aggregation, zeta potential, hydrodynamic size, size 
distribution and polydispersity index. 
 For in vivo analysis, in the case of BBB permeability, initial qualitative assessment using live 
imaging can be used to select a time point for quantification of NP permeation across the BBB using 
ICP-MS or NAA. 
 A comparison of NP levels, determined using ICP-MS or NAA, in different organs can leveraged for 
future work to enhance the targeting of NPs to the brain and away from other organs.  
 Qualitative assessment of CNS distribution using microscopy and co-localization techniques 
provides information regarding accumulation of NPs in different regions in the brain and routes by 
which various cells take up different NPs.  
 For measurement of BBB integrity following NP administration, a simple test using Evan’s Blue dye 
can be conducted. Historically, this has been a qualitative assessment, observing permeation of the 
dye into the brain. However, the brain can further be sectioned and the permeation of the dye can be 
quantified spectrophotometrically.  
 In the case of toxicity testing, systemic and CNS toxicity can be initially assessed qualitatively using 
histopathology and microscopy, respectively. Hematology can also be employed in systemic toxicity 
evaluations. These preliminary examinations can provide information to inform more specific 
testing, such as organ specific toxicity evaluations or cell specific IHC. 
 
Together, these tests offer an indication of the safety and efficacy of different NPs as potential drug delivery 
vehicles for CNS disease treatment. The recommended NP characterization and testing should be considered 
a minimum level of testing for all metallic-based NPs. However, the design of novel NPs results in the 
materials with unique properties that cannot be fully captured by the highlighted test methods. Instead, NP 
specific testing can be conducted to promote the unique characteristics of the novel nanomaterials and 
















compared to existing NPs while still emphasizing the novel material properties. Similarly, in vivo testing can 
be supplemented with application and NP specific testing. 
The use of in vivo models, however, can be arduous and costly to conduct. Strict ethical guidelines leave 
little scope for comparative models and novel NP assessments. Therefore, there is the need to develop an in 
vitro platform which closely mimics in vivo BBB properties. Such a model can be used to make valid 
predictions about BBB crossing and interactions of different NPs. Reproducible models can be used to 
complete comparative studies of different of NPs to better understand NP-BBB interactions. Microfluidic 
devices or ‘blood-brain barrier-on-a-chip’ devices are an interesting future avenue for research in the area of 
in vitro mimetics [158, 159]. As research strives to minimize the requirement for animal studies, these 
models become increasingly pivotal. Promising results at an in vitro stage will identify NPs that should be 
selected for more in-depth in vivo assessments. 
In the future, the concerted characterization and in vivo testing of NPs may feed into a public database of NP 
parameters and behaviors. This reference data library would detail NP properties and the resulting in vivo 
responses. Data on NPs will be made accessible to the different users which will boost data sharing and ease 
comparisons between laboratories, nanocarriers, or applications. Such a database may be accessed during 
future research to compare the properties and host system responses of novel NPs to existing datasets. This 
will improve the reproducibility of experimentation and advance the understanding of how different 
properties impact host system responses. This, in turn, will facilitate the selection of delivery systems best 
suited to specific clinical applications. As the database expands, for each new therapeutic application, 
suitable NP carriers may be selected for testing. This will minimize duplication of work, saving time and 
resources. It could also be leveraged by pharmaceutical companies to advance drug development, decrease 
the requirement for large scale screening and reduce time-to-market. However, such a database will be most 
useful when all researchers characterize and test their NPs in a comprehensive and consistent manner. This is 
crucial to enable comparisons to be made, which is critical to the advancement of this research area.  
It is the recommendation of this review that it is necessary to move towards standardized, universally 
available, and accepted methods for characterizing NPs and assessing their in vivo responses. Similar 
standardization should also be adopted for NPs of other materials, such as polymers and lipids, using 
techniques suitable for assessing these materials. Without such standardized approaches, comparisons of NPs 
for use in CNS drug delivery are not possible. This will inhibit progression towards the development of 
vehicles suitable for the delivery of lifesaving drugs to the CNS. 
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Figure 1: Workflow diagram summarizing the sourcing of papers to review and the exclusion criteria used. 
Based on the PRISMA flow diagram [44]. 
Figure 2: The percentage of papers reviewed that analyzed different nanoparticle properties using 
transmission electron microscopy (TEM) and dynamic light scattering (DLS), to the best of the authors’ 
knowledge.  
Figure 3: Flow diagram of the suggested minimum NP characterization to be carried out, including medium 
for NP dispersion, method or instrument to be used, and the parameters to be reported.  
Figure 4: The percentage of papers reviewed that analyzed different in vivo parameters during nanoparticle 
testing, to the best of the authors’ knowledge (BBB = blood-brain barrier; CNS = Central Nervous System).  
Figure 5: Flow diagram of the suggested minimum parameters to be evaluated during in vivo NP testing and 
the recommended techniques for evaluating these parameters (NP= nanoparticle; ICP-MS = inductively 
coupled plasma mass spectroscopy; NAA = neutron activation analysis; IHC = immunohistochemistry). 
Figure 6: Summary of the recommended approach to NPs characterization and in vivo testing of metallic-
based NPs for applications in central nervous system drug delivery (NP = nanoparticle, TEM = transmission 
electron microscopy, DLS = dynamic light scattering, NAA = neutron activation analysis, ICP-MS = 
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 Metallic-based nanoparticle characterization and in vivo testing is highly varied 
 Incomplete characterization complicates understanding in vivo responses 
 Widely available techniques for testing should be used to examine nanoparticles 
 Standardization could improve nanomedicine comparability, advancing drug delivery 
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